Table 1.
Clinical characteristics of male and female HL patients
| Characteristics | Total n (%) | Male n (%) | Female n (%) | p |
|---|---|---|---|---|
| Stage | 0.007 | |||
| I | 41 (10.5) | 24 (10.0) | 17 (11.2) | |
| II | 197 (50.4) | 109 (45.6) | 88 (57.9) | |
| III | 110 (28.1) | 70 (29.3) | 40 (26.5) | |
| IV | 43 (11.0) | 36 (15.1) | 7 (4.6) | |
| Extranodal disease | 31 (7.9) | 17 (7.8) | 14 (9.2) | 0.610 |
| Spleen | 61 (15.6) | 45 (18.8) | 16 (10.5) | 0.030 |
| Liver | 28 (7.2) | 20 (8.4) | 8 (5.3) | 0.255 |
| Bulky disease | 36 (9.2) | 22 (9.2) | 14 (9.2) | 0.850 |
| “B” symptoms present | 142 (36.3) | 104 (43.5) | 38 (25.0) | 0.019 |
| Histology | 0.036 | |||
| NLPHL | 30 (7.7) | 19 (8.0) | 11 (7.2) | |
| LRHL | 9 (2.3) | 6 (2.5) | 3 (2.0) | |
| MCHL | 158 (40.4) | 111 (46.5) | 47 (30.9) | |
| NSHL | 167 (42.7) | 89 (37.2) | 78 (51.3) | |
| LDHL | 5 (1.3) | 2 (0.8) | 3 (2.0) | |
| Not defined | 22 (5.6) | 12 (5.0) | 10 (6.6) | |
| ECOG Performance score | 0.208 | |||
| 0 | 178 (45.5) | 104 (43.5) | 74 (48.7) | |
| 1 | 151 (38.6) | 91 (38.1) | 60 (39.4) | |
| 2 | 48 (12. 3) | 36 (15.1) | 12 (8.0) | |
| 3 | 14 (3.6) | 8 (3.3) | 6 (3.9) |
HL: Hodgkin’s lymphoma; NLPHL: nodular lymphocyte predominant HL; LRHL: lymphocyte-rich HL; MCHL: mixed cellularity HL; NSHL: nodular sclerosing HL; LDHL: lymphocyte depletion HL; ECOG: Eastern Cooperative Oncology Group